drugset / Trial / NCT00939874
Switch From Tenofovir to Raltegravir for Low Bone Mineral Density
Phase 4
Completed
52 enrolled
St Vincent's Hospital, Sydney
Holdsworth House Medical Practice · collabMerck Sharp & Dohme LLC · collabThe Alfred · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if low bone mineral density (a measurement of how thick and strong bones are) improves in adults with HIV infection who switch their HIV medication tenofovir to another HIV medication raltegravir. Hypothesis:That Bone Mineral Density (BMD) will improve in osteopenic or osteoporotic patients switching from ART including tenofovir disoproxil fumarate (TDF) and a ritonavir-boosted protease inhibitor (r/PI) to ART including RAL+r/PI.
Timeline
- Start
- 2009-10
- Primary completion
- 2012-06
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Raltegravir | Other / unclassified | 400 mg | Oral |